{"prompt": "['MC1752', '71', '17.2', 'Diagnostic Slides from Original and /or Recurrent Tissue', 'Archived tissue may be collected per table 17.1 through next generation sequencing for', 'mRNA expression and whole genome analysis', 'Block retrieval and cutting will be determined at a later date.', '17.3', 'Correlative Tissue Collection', '17.31 Tissue Kits will not be provided for this protocol.', '17.32', 'Paraffin Embedded Tissue', '17.321', 'Archived tissue may be collected per table 17.1 through next', 'generation sequencing for mRNA expression and whole genome', 'analysis', '17.322', 'Block retrieval and cutting will be determined at a later date.', 'Shipping, accessioning, and processing information will be determined', 'at a later date. A modification will be submitted when information is', 'available.', '17.4', 'Background and Methodology', '17.41', 'See section 1.5 for correlative background information.', '17.42', 'Archived tissue may be collected per table 17.1 through next generation', 'sequencing for mRNA expression and whole genome analysis.', 'Protocol Version Date: 21JUN2018']['MC1752', '72', '18.0', 'Records and Data Collection Procedures', '18.1', 'Data submission instructions', 'Data submission instructions for this study can be found in the Data Submission', 'Schedule.', '18.2', 'Survival Follow-up', 'Not applicable. Patients will be followed until EOS visit (12 months) only.', '18.3', 'CRF completion', 'This study will use Medidata Rave for remote data capture (rdc) of all study data. Data', 'collection for this study will be done exclusively through the Medidata Rave clinical data', 'management system. Access to the trial in Rave is granted through the iMedidata', 'application to all persons with the appropriate roles assigned in Regulatory Support', 'System (RSS). To access Rave via iMedidata, the site user must have an active account', 'and the appropriate Rave role (Rave CRA, Read-Only, Site Investigator) on either the', 'organization roster at the enrolling site.', '18.4', 'Site responsibilities', \"Each site will be responsible for insuring that all materials contain the patient's initials,\", \"MCCC registration number, and MCCC protocol number. Patient's name must be\", 'removed.', '18.5', 'Supporting documentation', 'This study requires supporting documentation for diagnosis prior to study entry as well as', 'for evidence of response to study therapy and progression after study therapy. 18.6', 'Labeling of materials', \"Each site will be responsible for insuring that all materials contain the patient's initials,\", \"MCCC registration number, and MCCC protocol number. Patient's name must be\", 'removed.', '18.7', 'Overdue lists', 'A list of overdue forms and outstanding queries will be available in Rave through the', 'Rave Task Summary. In addition to this, the Overdue Materials report is available on the', 'Cancer Center Systems homepage.', '19.0', 'Budget Considerations', '19.1', 'Tests to be research funded: Avelumab Study drug, Avelumab study drug administration,', 'ECG, urogram at EOS visit (12 month after registration), obtaining and processing of', 'archived research tissue specimens.', 'Protocol Version Date: 21JUN2018']['MC1752', '73', '20.0', 'References', '1.', 'Mak RH, Hunt D, Shipley WU et al. Long-term outcomes in patients with muscle-invasive', 'bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of', 'Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol', '2014; 32: 3801-3809.', '2.', 'Gogna NK, Matthews JH, Turner SL et al. Efficacy and tolerability of concurrent weekly low', 'dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma:', 'a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiother', 'Oncol 2006; 81: 9-17.', '3.', 'Hagan MP, Winter KA, Kaufman DS et al. RTOG 97-06: Initial report of a Phase I-II trial of', 'selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin,', 'and adjuvant MCV combination chemotherapy. International Journal of Radiation', 'Oncology*Biology*Physics 2003; 57: 665-672.', '4.', 'James ND, Hussain SA, Hall E et al. Radiotherapy with or without Chemotherapy in Muscle-', 'Invasive Bladder Cancer. New England Journal of Medicine 2012; 366: 1477-1488.', '5.', 'Kaufman DS, Winter KA, Shipley W et al. Muscle-invading bladder cancer, RTOG Protocol 99-', '06: Initial report of a phase I/II trial of selective bladder-conservation employing TURBT, accelerated', 'irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine', 'chemotherapy. J Clin Oncol 2005; 23.', '6.', 'Kaufman DS, Winter KA, Shipley WU et al. The initial results in muscle-invading bladder cancer', 'of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin', 'and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial', 'response. Oncologist 2000; 5: 471-476.', '7.', 'Mitin T, Hunt D, Shipley WU et al. Transurethral surgery and twice-daily radiation plus', 'paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant', 'chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre', 'phase 2 trial. The lancet oncology 2013; 14: 863-872.', '8.', 'Shipley WU, Winter KA, Kaufman DS et al. Phase III trial of neoadjuvant chemotherapy in', 'patients with invasive bladder cancer treated with selective bladder preservation by combined radiation', 'therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol', '1998; 16: 3576-3583.', '9.', 'Tester W, Caplan R, Heaney J et al. Neoadjuvant combined modality program with selective', 'organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II', 'trial 8802. Journal of Clinical Oncology 1996; 14: 119-126.', '10.', 'Tester W, Porter A, Asbell S et al. Combined modality program with possible organ preservation', 'for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993; 25:', '783-790.', '11.', 'Giacalone NJ, Shipley WU, Clayman RH et al. Long-term Outcomes After Bladder-preserving', 'Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the', 'Massachusetts General Hospital Experience. Eur Urol 2017.', '12.', 'Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the', 'immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.', '13.', 'Sistigu A, Yamazaki T, Vacchelli E et al. Cancer cell-autonomous contribution of type I', 'interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20: 1301-1309.', '14.', 'Wu CT, Chen WC, Chang YH et al. The role of PD-L1 in the radiation response and clinical', 'outcome for bladder cancer. Sci Rep 2016; 6: 19740.', '15.', 'Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced', 'and metastatic urothelial carcinoma who have progressed following treatment with platinum-based', 'chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387: 1909-1920.', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}